



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/1/2019
LAST REVIEW DATE: 5/21/2020
LAST CRITERIA REVISION DATE: 5/21/2020
ARCHIVE DATE:

FORTEO (teriparatide) subcutaneous injection TYMLOS (abaloparatide) subcutaneous injection

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

FORTEO (teriparatide) subcutaneous injection
TYMLOS (abaloparatide) subcutaneous injection

Forteo (teriparatide)

- **Criteria for initial therapy:** Forteo (teriparatide) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Endocrinologist, Rheumatologist, Gynecologist, Geriatrician, Physiatrist, or Orthopedic Specialist
 2. Individual is 18 years of age or older
 3. Individual with **ONE** of the following:
 - Established osteoporosis [T-score of -2.5 or worse (e.g., -3.0, -3.5, etc.)]
 - Osteopenia [T-score of -1.0 or worse] with a history of prior fragility fracture
 - A low trauma fragility bone fracture
 - At high risk for fracture as evidenced by multiple factors such as significantly low bone mass, frequent falls, limited movement, medical conditions likely to cause bone loss, medicines that may cause bone loss, (e.g., seizure medicines, blood thinners, high doses of vitamins A or D)
 - Individual with a FRAX 10-year probability risk of 3% or more for a hip fracture **OR** 20% or more for other bone fracture, as assessed by the World Health Organization Fracture Risk Assessment Tool (FRAX tool) that can be obtained at <https://www.sheffield.ac.uk/FRAX/tool.aspx?country=9>
 - Glucocorticoid-induced osteoporosis at high risk for fracture associated with current and sustained use of Prednisone (or equivalent glucocorticoid) at a daily dose of 5 mg or more and expected to remain on glucocorticoids for 3 months or more
 4. Individual has failed, or is intolerant to, or has a contraindication to at least **ONE** of the following agents:
 - Alendronate
 - Ibandronate
 - Risedronate
 - Zoledronic acid
 5. Individual is receiving supplemental calcium **AND** vitamin D with doses adjusted per usual laboratory monitoring
 6. No dual therapy with another parathyroid hormone related product such as: Tymlos (abaloparatide) or Natpara (parathyroid hormone)
 7. No previous use of another parathyroid hormone related product of 2 years duration

FORTEO (teriparatide) subcutaneous injection
TYMLOS (abaloparatide) subcutaneous injection

8. **ALL** of the following baseline tests have been completed before initiation of treatment with continued monitoring as clinically appropriate:
- Alkaline phosphatase
 - Parathyroid hormone
 - Serum calcium
 - Serum phosphorus
 - Serum uric acid

Initial approval duration: 12 months if previous use of any drug in this drug category is less than 12 months

- **Criteria for continuation of coverage (renewal request):** Forteo (teriparatide) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Endocrinologist, Rheumatologist, Gynecologist, Geriatrician, Psychiatrist, or Orthopedic Specialist
 2. Individual's condition responded while on
 - Response is defined as:
 - Achieved and maintains increased bone mineral density (e.g., lumbar spine, femoral neck, or total hip) and **ONE** of the following:
 - Reduced incidence of new vertebral fractures in previously non-deformed vertebrae
 - Reduced incidence of non-vertebral fractures (e.g., ankle/foot, hip, humerus, pelvis, wrists, or other sites)
 - No evidence of disease progression
 3. Individual has been adherent with the medication
 4. Individual is receiving supplemental calcium **AND** vitamin D with doses adjusted per usual laboratory monitoring
 5. No dual therapy with another parathyroid hormone related product such as: Tymlos (abaloparatide) or Natpara (parathyroid hormone)
 6. No previous use of another parathyroid hormone related product of 2 years duration
 7. Individual has not developed any significant unacceptable level 4 adverse drug effects that may exclude continued use
 - Significant adverse effect such as:
 - Hypersensitivity to teriparatide or any of its excipients
 - Osteosarcoma
 - Severe or sustained hypercalcemia

FORTEO (teriparatide) subcutaneous injection TYMLOS (abaloparatide) subcutaneous injection

- Hypercalciuria (urine calcium > 300mg/24 hours or > 7.5 mmol/24 hours)
- Hypophosphatemia (< 0.74 mmol/L or 2.4 mg/dL)

Renewal duration: 12 months if previous use of any drug in this drug category is less than 24 months

Tymlos (abaloparatide)

- **Criteria for initial therapy:** Tymlos (abaloparatide) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Endocrinologist, Rheumatologist, Gynecologist, Geriatrician, Physiatrist, or Orthopedic Specialist
 2. Individual is 18 years of age or older
 3. Individual with **ONE** of the following:
 - Established osteoporosis [T-score of -2.5 or worse (e.g., -3.0, -3.5, etc.)]
 - Osteopenia [T-score of -1.0 or worse] with a history of prior fragility fracture
 - A low trauma fragility bone fracture
 - At high risk for fracture as evidenced by multiple factors such as significantly low bone mass, frequent falls, limited movement, medical conditions likely to cause bone loss, medicines that may cause bone loss, (e.g., seizure medicines, blood thinners, corticosteroids, high doses of vitamins A or D)
 - Individual with a FRAX 10-year probability risk of 3% or more for a hip fracture **OR** 20% or more for other bone fracture, as assessed by the World Health Organization Fracture Risk Assessment Tool (FRAX tool) that can be obtained at <https://www.sheffield.ac.uk/FRAX/tool.aspx?country=9>
 4. Individual has failed, or is intolerant to, or has a contraindication to at least **ONE** of the following agents:
 - Alendronate
 - Ibandronate
 - Risedronate
 - Zoledronic acid
 5. Individual is receiving supplemental calcium **and** vitamin D with doses adjusted per usual laboratory monitoring
 6. No dual therapy with another parathyroid hormone related product such as: Forteo (teriparatide) or Natpara (parathyroid hormone)

FORTEO (teriparatide) subcutaneous injection TYMLOS (abaloparatide) subcutaneous injection

7. No previous use of another parathyroid hormone related product of 2 years duration
8. **ALL** of the following baseline tests have been completed before initiation of treatment with continued monitoring as clinically appropriate:
 - Alkaline phosphatase
 - Parathyroid hormone
 - Serum calcium
 - Serum phosphorus
 - Serum uric acid

Initial approval duration: 12 months if previous use of any drug in this drug category is less than 12 months

- **Criteria for continuation of coverage (renewal request):** Tymlos (abaloparatide) is considered **medically necessary** and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Endocrinologist, Rheumatologist, Gynecologist, Geriatrician, Physiatrist, or Orthopedic Specialist
 2. Individual's condition responded while on
 - Response is defined as:
 - Achieved and maintains increased bone mineral density (e.g., lumbar spine, femoral neck, or total hip) and **ONE** of the following:
 - Reduced incidence of new vertebral fractures in previously non-deformed vertebrae
 - Reduced incidence of non-vertebral fractures (e.g., ankle/foot, hip, humerus, pelvis, wrists, or other sites)
 - No evidence of disease progression
 3. Individual has been adherent with the medication
 4. Individual is receiving supplemental calcium **and** vitamin D with doses adjusted per usual laboratory monitoring
 5. No dual therapy with another parathyroid hormone related product such as: Forteo (teriparatide) or Natpara (parathyroid hormone)
 6. No previous use of another parathyroid hormone related product of 2 years duration
 7. Individual has not developed any significant unacceptable level 4 adverse drug effects that may exclude continued use
 - Significant adverse effect such as:
 - Osteosarcoma

FORTEO (teriparatide) subcutaneous injection
TYMLOS (abaloparatide) subcutaneous injection

- Severe or sustained hypercalcemia
- Hypercalciuria (urine calcium > 300mg/24 hours or > 7.5 mmol/24 hours)

Renewal duration: 12 months if previous use of any drug in this drug category is less than 24 months

➤ Forteo (teriparatide) and Tymlos (abaloparatide) for all other indications not previously listed or if above criteria not met is considered **experimental or investigational** based upon:

1. Lack of final approval from the Food and Drug Administration, and
2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and
3. Insufficient evidence to support improvement of the net health outcome, and
4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, and
5. Insufficient evidence to support improvement outside the investigational setting.

These indications include, *but are not limited to*:

Treatment with dosing or frequency outside the FDA-approved dosing and frequency

Description:

Forteo (teriparatide) is a recombinant form of human parathyroid hormone [rhPTH] that is the primary regulator of bone and mineral metabolism. Forteo may be used for treatment of osteoporosis in postmenopausal women, to increase bone mass in men with osteoporosis and for treatment of women and men with osteoporosis associated with sustained systemic glucocorticoid therapy. Generally, Forteo is given as a 2 year course of treatment.

Tymlos (abaloparatide) is an analog of human parathyroid hormone related peptide [PTHrP(1-34)] indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture or individuals who have failed or are intolerant to other available osteoporosis therapy.

The use of Forteo or Tymlos is not recommended in patients at increased risk of osteosarcoma including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton.

Cumulative use of Forteo and Tymlos and parathyroid hormone for more than 2 years during a patient's lifetime is not recommended.

**FORTEO (teriparatide) subcutaneous injection
TYMLOS (abaloparatide) subcutaneous injection**

Definitions:

Adult: Age 18 years and older

T-Scores are reported as standard deviations (SD) World Health Organization (WHO) criteria:

Normal:	T-score within 1 SD
Osteopenia:	T-score of -1 to -2.5 SD
Osteoporosis:	T-score of -2.5 or worse SD
Severe Osteoporosis:	T-score of -2.5 or worse SD with fragility fractures

High risk for fracture is defined as ONE of the following:

- Osteoporotic fracture
- Multiple risk factors for fracture (significantly low bone mass, frequent falls, limited movement, medical conditions likely to cause bone loss, medicines that may cause bone loss, e.g., seizure medicines, blood thinners, corticosteroids, high doses of vitamins A or D)
- Failed response (as defined by prescribing provider) to previous osteoporosis therapy
- Intolerant to previous osteoporosis therapy

Fragility fracture:

A fracture occurring spontaneously or after a minor trauma.

Fracture Risk Assessment Tool (FRAX tool):

The World Health Organization developed a risk assessment tool to assist providers in evaluating osteopenic individuals. The tool uses clinically proven risk factors to determine a 10 year probability of hip fracture and a 10 year probability for a major osteoporotic fracture (clinical spine, forearm, hip or shoulder fractures). Treatment may be considered if the 10-year risk is 3% or more for hip fracture or if the risk for other bone fracture is 20% or more.

The tool can be obtained at <https://www.sheffield.ac.uk/FRAX/tool.aspx?country=9>

Glucocorticoid Equivalencies:

Betamethasone	0.75 mg
Cortisone	25 mg
Dexamethasone	0.75 mg
Hydrocortisone	20 mg
Methylprednisolone	4 mg
Prednisone	5 mg
Prednisolone	5 mg

Resources:

Forteo (teriparatide) product information accessed 02-19-20 at DailyMed

Tymlos (abaloparatide) product information accessed 02-19-20 at DailyMed



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/1/2019
LAST REVIEW DATE: 5/21/2020
LAST CRITERIA REVISION DATE: 5/21/2020
ARCHIVE DATE:

FORTEO (teriparatide) subcutaneous injection
TYMLOS (abaloparatide) subcutaneous injection

UpToDate: Overview of the management of osteoporosis in postmenopausal women. Current through Nov 2018

UpToDate: Treatment of osteoporosis in men. Current through Nov 2018

UpToDate: The use of bisphosphonates in postmenopausal women with osteoporosis. Current through Nov 2018

UpToDate: Prevention and treatment of glucocorticoid-induced osteoporosis. Current through Nov 2018

American College of Physicians, Qaseem, A, et al. Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians. 2008;148:680-684.

American College of Rheumatology, Gluck, O, Maricic, M. Teriparatide (Forteo) for the Treatment of Osteoporosis. *HOTLINE*. 01/2003.

Black, D, Greenspan, S, al e. The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis. *The New England Journal of Medicine*. 09/25/2003;349(No. 13):1207-1215.

Brunader, R, Shelton, D. Radiologic Bone Assessment in the Evaluation of Osteoporosis. *American Family Physician*. 04/01/2002.

CenterWatch Clinical Trials Listing Service™. Drugs Approved by the FDA Drug Name: Forteo (teriparatide). 12/30/2002.

External Consultant Review. Clinical Pharmacy. 05/13/2008.

FDA. Forteo Approval Letter. 11/26/2002.

Finkelstein, J, Hayes, A, al e. The Effects of Parathyroid Hormone, Alendronate, or Both in Men With Osteoporosis. *The New England Journal of Medicine*. 09/25/2003;349(No. 13):1216-1226.

Forteo. Package Insert. Accessed 10/09/2015.

Hodsman, A, Bauer, D, et, al. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use. *Endocrine Reviews*. 2005;26(5):688-703.

International Society for Clinical Densitometry. 2007 Official Positions.

Khosla, S. Parathyroid Hormone Plus Alendronate A Combination That Does Not Add Up. *The New England Journal of Medicine*. 09/25/2003;349(No. 13):1277-1279.

Liu, H, Paige, N, et, al. Screening for Osteoporosis in Men: A Systematic Review for an American College of Physicians Guideline. *Annals of Internal Medicine*. 05/2008;148(9).



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 4/1/2019
LAST REVIEW DATE: 5/21/2020
LAST CRITERIA REVISION DATE: 5/21/2020
ARCHIVE DATE:

FORTEO (teriparatide) subcutaneous injection
TYMLOS (abaloparatide) subcutaneous injection

MacLean, C, Newberry, S, et, al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. *Annals of Internal Medicine*. 2008.

Migliaccio, S, Brama, M, Malavolta, N. Management of Glucocorticoids-induced Osteoporosis: Role of Teriparatide. *Therapeutics and Clinical Risk Management*. 2009;5:305-310.

National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Center. Osteoporosis in Men. 05/2009.

Saag, K, Shane, E, et, al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. *N Engl J Med*. 2007;357:2028-2039.

Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. *Arthritis and rheumatism*. Nov 2009;60(11):3346-3355.

Summey, B, Yosipovitch, G. Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update. *Arch Dermatol*. 2006;142:82-90.

Forum CTA. Vitamin D for the Prevention of Osteoporotic Fractures. *Blue Shield of California Foundation*. 02/16/2011.
